| Cat. No. |
Product Name |
Information |
| PC-49186 |
SF235
Mip inhibitor
|
SF235 is a small-molecule inhibitor of macrophage infectivity potentiator (Mip) protein with IC50 and Ki 0.42 and 0.29 uM against B. pseudomallei Mip (BpMip) peptidyl-prolyl cis/trans isomerase (PPIase) activity, reduce B. pseudomallei virulence in vitro. |
| PC-49180 |
BDM71339
EthR inhibitor
|
BDM71339 is the first small molecule inhibitor of mycobacterial transcriptional regulator EthR, boosts ten times the activity of ethionamide in TB-infected macrophages at low nanomolar concentrations (EC50=72 nM) in vitro. |
| PC-49179 |
BVL-GSK098
M.tb VirS inhibitor
|
BVL-GSK098 (Alpibectir) is a small molecule able to inhibit Mycobacterium tuberculosis transcription regulator VirS, boosts bioactivation of ethionamide (ETH) and lower ETH MIC. |
| PC-49166 |
TXA707
FtsZ inhibitor
|
TXA707 is the active metabolite of TXA709 and bacterial protein FtsZ inhibitor, maintains potent activity against S. aureus strains (e.g., MRSA, VRSA, DNSSA, and LNSSA) that are resistant to current SOC antibiotics. |
| PC-49165 |
TXY541
FtsZ inhibitor
|
TXY541 is a 1-methylpiperidine-4-carboxamide prodrug of PC190723 and bacterial protein FtsZ inhibitor, TXY541 is efficacious in vivo in mouse models of systemic infection with both methicillin-sensitive and methicillin-resistant S. aureus. |
| PC-49164 |
TXA709
FtsZ inhibitor
|
TXA709 is a prodrug of FtsZ-targeting benzamide compound (TXA707) with enhanced metabolic stability, demonstrates improved pharmacokinetic properties, and superior in vivo antistaphylococcal efficacy (both oral and intravenous) relative to previously identified prodrugs (TXY436 and TXY541) of PC190723. |
| PC-49163 |
TXA6101
FtsZ inhibitor
|
TXA6101 is an FtsZ-targeting compound with activity against MRSA isolates that express either G196S or G193D mutant FtsZ proteins, shows potent in vitro antibacterial activity against MRSA clinical isolate MPW020 with MIC of 0.125 ug/mL. |
| PC-49162 |
Sudapyridine
Antituberculosis
|
Sudapyridine (WX-081) is a potential new antituberculosis compound,excellent antimicrobial in vitro activity against both drug-susceptible and drug-resistant M. tuberculosis clinical isolates with MICs of 0.117 to 0.219 ug/mL. |
| PC-49157 |
JBD1
S. aureus biofilm inhibitor
|
JBD1 is a small molecule compound that strongly inhibits biofilm formation of S. aureus, including methicillin-resistant strains, induces biofilm inhibition and metabolic remodeling through respiratory activation. |
| PC-49113 |
MD-124
Antibiotic adjuvant
|
MD-124 is a potent antibiotic adjuvant against Gram-negative bacteria, sensitizes various Gram-negative bacterial species and strains, including multidrug resistant pathogens, toward existing antibiotics. |
| PC-49008 |
Fleroxacin
Antibiotic
|
Fleroxacin (AM833, Ro23-6240) is a broad-spectrum fluoroquinolone antibiotic, with activity against a variety of Gram-positive and Gram-negative bacteria with MIC90 values of 0.05 to 3.13 ug/mL. |
| PC-47040 |
Brilacidin tetrahydrochloride
Antiviral compound
|
Brilacidin (PMX-30063) is a synthetic, non-peptide, defensin-mimetic compound, exhibits broad-spectrum anti-microbial and anti-SARS-CoV-2 activities. |
